Overview

Sapropterin on Cognitive Abilities in Young Adults With Phenylketonuria

Status:
Terminated
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2a multicenter, double-blind, placebo-controlled, randomized, 2-arm pilot trial designed to assess the effect of sapropterin on cognitive abilities in young adults with Phenylketonuria (PKU) over a 26-week treatment period.
Phase:
Phase 2
Details
Lead Sponsor:
BioMarin Pharmaceutical
Merck KGaA
Treatments:
Verapamil